Institute of Biomedicine, University of Turku, Turku, Finland.
Department of Infectious Diseases, Meilahti Vaccination Research Center, MeVac, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Nat Commun. 2021 Jun 28;12(1):3991. doi: 10.1038/s41467-021-24285-4.
As SARS-CoV-2 has been circulating for over a year, dozens of vaccine candidates are under development or in clinical use. The BNT162b2 mRNA COVID-19 vaccine induces spike protein-specific neutralizing antibodies associated with protective immunity. The emergence of the B.1.1.7 and B.1.351 variants has raised concerns of reduced vaccine efficacy and increased re-infection rates. Here we show, that after the second dose, the sera of BNT162b2-vaccinated health care workers (n = 180) effectively neutralize the SARS-CoV-2 variant with the D614G substitution and the B.1.1.7 variant, whereas the neutralization of the B.1.351 variant is five-fold reduced. Despite the reduction, 92% of the seronegative vaccinees have a neutralization titre of >20 for the B.1.351 variant indicating some protection. The vaccinees' neutralization titres exceeded those of recovered non-hospitalized COVID-19 patients. Our work provides evidence that the second dose of the BNT162b2 vaccine induces cross-neutralization of at least some of the circulating SARS-CoV-2 variants.
随着 SARS-CoV-2 持续传播超过一年，数十种疫苗候选物正在开发或临床使用中。BNT162b2 mRNA COVID-19 疫苗可诱导与保护性免疫相关的刺突蛋白特异性中和抗体。B.1.1.7 和 B.1.351 变体的出现引起了人们对疫苗效力降低和再感染率增加的担忧。在这里，我们表明，在第二剂后，接受 BNT162b2 疫苗接种的医护人员（n=180）的血清可有效中和具有 D614G 取代和 B.1.1.7 变体的 SARS-CoV-2 变体，而对 B.1.351 变体的中和作用则降低了五倍。尽管有所减少，但 92%的血清阴性疫苗接种者对 B.1.351 变体的中和滴度>20，表明存在一定的保护作用。疫苗接种者的中和滴度超过了未住院的 COVID-19 患者的恢复水平。我们的工作提供了证据，表明 BNT162b2 疫苗的第二剂可诱导对至少一些循环 SARS-CoV-2 变体的交叉中和。
